Pacific Bio (PACB) Reports In-Line Q4 EPS, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts PACB Hot Sheet
Join SI Premium – FREE
Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $39.2 million versus the consensus estimate of $40.61 million.
For earnings history and earnings-related data on Pacific Bio (PACB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Veralto Corporation (VLTO) Tops Q3 EPS by 23c; raises guidance
- Bayfirst Financial Corp (BAFN) Tops Q3 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
